Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Just a few days after lining up $57.5 million in near-term cash from a high-profile collaboration deal with AstraZeneca on its Anticalin platform, one of Pieris’ other partners unceremoniously swept out one of their clinical-stage therapies in a Q1 pipeline cleanup.
DS-9001 was dropped by Daiichi Sankyo after investigators reviewed the data they had on the Phase I therapy targeting PCSK9. Pieris $PIRS has been working for years on engineering proteins that are lighter and more versatile than antibodies, so that they can work where antibodies find their entry barred.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.